PDRN CareDNA Fragments in Regenerative Therapy
Dr. Sarah Chen
PhD, Molecular Biology
DNA fragment therapy encompasses the medical and cosmetic use of purified, deproteinized polynucleotide chains β primarily polydeoxyribonucleotide (PDRN) and polynucleotide (PN) β to stimulate tissue regeneration, reduce inflammation, and accelerate wound healing [1].
Definition
DNA fragment therapy encompasses the medical and cosmetic use of purified, deproteinized polynucleotide chains β primarily polydeoxyribonucleotide (PDRN) and polynucleotide (PN) β to stimulate tissue regeneration, reduce inflammation, and accelerate wound healing [1]. These biologically active polymers, extracted from the sperm cells of Oncorhynchus mykiss (rainbow trout) or Oncorhynchus keta (chum salmon), represent a class of regenerative therapeutics that harness the building blocks of DNA itself to fuel the body's repair mechanisms. DNA fragment therapy forms the scientific foundation for an expanding range of injectable treatments, topical skincare products, and clinical protocols in dermatology, orthopedics, ophthalmology, and wound care [4].
Historical Development
The therapeutic use of DNA-derived substances dates to the mid-20th century, when European researchers first investigated nucleic acid extracts for wound healing applications. Early preparations were crude tissue extracts with inconsistent composition and efficacy. The modern era of DNA fragment therapy began in the 1980s and 1990s in Italy, where pharmaceutical researchers at Mastelli Srl developed standardized extraction and purification processes to isolate PDRN from salmon sperm cells with reproducible molecular weight distributions and purity levels [1][2].
The Italian pharmaceutical company obtained the first regulatory approvals for injectable PDRN (marketed as Placentex) for the treatment of dystrophic ulcers, peripheral arterial disease-related tissue ischemia, and diabetic foot wounds. These early medical applications established the safety profile and biological mechanism of action that would later be translated to aesthetic and cosmetic dermatology [1]. The expansion of DNA fragment therapy into skincare accelerated dramatically in the 2010s, driven largely by Korean dermatology clinics that recognized PDRN's potential for skin rejuvenation, popularizing injectable skin boosters like the Rejuran product line.
Production: From Salmon to Serum
PDRN is produced through a multi-step extraction and purification process that transforms raw biological material into a pharmaceutical-grade active ingredient [2]:
Source material selection: Sperm cells from Oncorhynchus species are chosen because they contain an exceptionally high concentration of DNA relative to other cellular components, and because salmon DNA has over 95% sequence homology with human DNA at the nucleotide level [2]. This genetic similarity is important β it means the degradation products of salmon-derived PDRN produce nucleosides and nucleotides that are biochemically identical to those the human body uses for its own DNA metabolism.
Extraction and deproteinization: The raw cellular material undergoes enzymatic digestion and chemical treatment to remove all proteins, lipids, and other non-DNA components. This deproteinization step is critical for safety β it eliminates potential allergens and immunogenic proteins, leaving only purified DNA polymer chains [2]. The resulting product contains no species-specific proteins and cannot trigger immune responses based on its biological origin.
Controlled fragmentation: The purified DNA is subjected to controlled physical or enzymatic fragmentation to achieve target molecular weight distributions. Different product categories require different molecular weight ranges β injectable PDRN preparations typically contain fragments between 50,000 and 1,500,000 Daltons, while topical formulations may include a broader distribution with smaller fragments to improve skin penetration [1][2].
Sterilization and formulation: The purified, fragmented PDRN is sterilized, standardized for concentration, and formulated into its final delivery vehicle β injectable solution, serum, cream, or other cosmetic format.
Molecular Weight and Why It Matters
The molecular weight distribution of DNA fragment preparations determines both their mechanism of action and their clinical behavior [2]. Higher molecular weight PDRN (hundreds of thousands of Daltons) acts primarily as a slowly degrading depot that releases nucleosides and nucleotides over time as tissue enzymes cleave the polymer chains. This sustained release provides prolonged A2A receptor activation and continuous substrate supply to the salvage pathway.
Lower molecular weight fragments (thousands to tens of thousands of Daltons) are more rapidly metabolized and provide faster onset of action but shorter duration of effect. The smallest degradation products β individual deoxyribonucleosides like deoxyadenosine (molecular weight approximately 251 Da) β are the molecules that directly bind A2A receptors and enter the salvage pathway [1].
This molecular weight spectrum is why different PDRN products have different clinical profiles. Injectable skin boosters with higher molecular weight PDRN provide weeks of sustained regenerative activity. Topical serums with lower molecular weight fragments offer more immediate cellular uptake but require consistent daily application to maintain their effects.
Dual Mechanism of Action
DNA fragment therapy works through two complementary biological pathways [1][3]:
Adenosine A2A receptor activation: As PDRN chains are enzymatically cleaved in tissue, the released deoxyadenosine and adenosine molecules bind to adenosine A2A receptors on the surface of fibroblasts, endothelial cells, macrophages, and other cell types. A2A activation triggers a cAMP-mediated intracellular signaling cascade that produces three principal downstream effects: (1) increased fibroblast proliferation and collagen synthesis through CREB-mediated gene transcription; (2) suppression of pro-inflammatory cytokines including TNF-alpha, IL-6, and NF-kB; and (3) upregulation of VEGF expression promoting angiogenesis and improved tissue perfusion [1].
Nucleotide salvage pathway support: The nucleoside and nucleotide fragments from PDRN degradation are absorbed by cells and processed through the salvage pathway β a metabolic recycling system that converts pre-formed nucleosides back into nucleotide triphosphates (including ATP, GTP, CTP, and TTP) [1]. These recycled nucleotides are used for DNA repair, RNA synthesis, and cellular energy metabolism. The salvage pathway is significantly less energy-intensive than de novo nucleotide synthesis, making it particularly valuable in metabolically stressed tissue where ATP availability is limited.
Medical Applications Beyond Skincare
DNA fragment therapy has established clinical evidence across multiple medical specialties [1][4]:
Wound healing: PDRN injections accelerate healing of diabetic foot ulcers, venous leg ulcers, and post-surgical wounds by stimulating angiogenesis, fibroblast activity, and anti-inflammatory tissue remodeling. Clinical trials demonstrate significantly faster wound closure and improved tissue quality compared to standard wound care [4].
Orthopedics: Intra-articular PDRN injections show promise for osteoarthritis management, reducing joint inflammation and potentially supporting cartilage repair through chondrocyte stimulation. Studies report improvements in pain scores and joint function comparable to hyaluronic acid injections [1].
Ophthalmology: PDRN eye drops are used in corneal wound healing, particularly after refractive surgery (LASIK, PRK) and for dry eye syndrome. The corneal epithelium responds robustly to PDRN's regenerative signaling, with faster re-epithelialization and improved tear film stability [1].
Burns and radiation injury: PDRN's anti-inflammatory and pro-angiogenic properties make it effective for treating burns and radiation dermatitis, where tissue ischemia and inflammation are primary barriers to healing [4].
Current Research Frontiers
The science of DNA fragment therapy continues to evolve in several directions [3][4]. Researchers are investigating optimized molecular weight fractions for specific clinical applications, novel delivery systems (exosome-encapsulated PDRN, dissolving microneedle patches), combination protocols with growth factors and stem cell therapies, and the potential for PN/PDRN to modulate epigenetic aging markers. The expansion of clinical trial data, particularly large-scale randomized controlled trials, continues to build the evidence base that supports DNA fragment therapy's transition from aesthetic niche to mainstream regenerative medicine.
Distinction: PDRN vs. PN vs. HPT-DNA
Three related but distinct categories of DNA fragment products exist in the market [2]. PDRN (polydeoxyribonucleotide) refers specifically to purified DNA fragments with molecular weights between 50-1,500 kDa, produced under pharmaceutical-grade standards. PN (polynucleotide) is a broader term that includes both PDRN and RNA-containing nucleic acid preparations, often with higher molecular weight distributions. HPT-DNA (highly purified technology DNA) is a marketing term used by certain brands to describe their specific extraction process. While all three share the same fundamental mechanism of action, differences in molecular weight distribution, purity, and regulatory classification can affect clinical outcomes and product selection.
References
- [1]Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L, Altavilla D. Pharmacological Activity and Clinical Use of PDRN. Curr Pharm Des. 2017;23(27):3948-3957. doi:10.2174/1381612823666170516153716
- [2]Veronesi F, Dallari D, Sabbioni G, Carubbi C, Martini L, Fini M. Polydeoxyribonucleotides (PDRNs): From Physical Chemistry to Biological Activities β A Review. J Cell Physiol. 2017;232(12):3383-3393. doi:10.1002/jcp.25796
- [3]Kim TH, Kim JH, Kang YS, et al.. Polydeoxyribonucleotide Promotes Wound Healing by Increasing Angiogenesis and Collagen Synthesis. Int J Mol Sci. 2021;22(14):7483. doi:10.3390/ijms22147483
- [4]Colangelo MT, Galli C, Gentile P. The Effects of Polydeoxyribonucleotide on Wound Healing and Tissue Regeneration: A Systematic Review. J Clin Med. 2020;9(10):3274. doi:10.3390/jcm9103274